Roche Holding AG Pre-Tax Profit Margin 2010-2023 | RHHBY

Roche Holding AG pre-tax profit margin from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Roche Holding AG Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $738.227B 106.70
Novo Nordisk (NVO) Denmark $579.834B 47.77
Johnson & Johnson (JNJ) United States $364.311B 14.45
Merck (MRK) United States $326.254B 59.35
AbbVie (ABBV) United States $286.349B 14.76
AstraZeneca (AZN) United Kingdom $236.905B 20.60
Novartis AG (NVS) Switzerland $199.290B 14.13
Pfizer (PFE) United States $153.908B 19.14
Sanofi (SNY) $126.556B 11.94
Innoviva (INVA) United States $0.963B 6.80